NASDAQ : LGVN
Longeveron Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.32M |
| Enterprise Value | -4.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.04M |
| Shares Outstanding | 3.19M |
| Shares Change (YoY) | +64.79% |
| Shares Change (QoQ) | +26.59% |
| Owned by Insiders (%) | 17.83% |
| Owned by Institutions (%) | 15.45% |
| Float | 2.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.49 |
| Forward PS | 2.59 |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.63 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -203.61% |
| Return on Assets (ROA) | -90.95% |
| Return on Invested Capital (ROIC) | -118.32% |
| Return on Capital Employed (ROCE) | -209.79% |
| Weighted Average Cost of Capital (WACC) | 2.84% |
| Revenue Per Employee | $31,237 |
| Profits Per Employee | -$617,737 |
| Employee Count | 38 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.20 |
| 52-Week Price Change | -81.20% |
| 50-Day Moving Average | 3.90 |
| 200-Day Moving Average | 6.64 |
| Relative Strength Index (RSI) | 31.20 |
| Average Volume (20 Days) | 76,593 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 73,177 |
| Short Previous Month | 106,796 |
| Short % of Shares Out | 2.30% |
| Short % of Float | 3.10% |
| Short Ratio (days to cover) | 0.42 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.19M |
| Gross Profit | 828,000 |
| Operating Income | -23.46M |
| Pretax Income | -23.47M |
| Net Income | -23.47M |
| EBITDA | -22.44M |
| EBIT | -23.46M |
| Loss Per Share | -$9.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 10.08M |
| Total Debt | 581,000 |
| Net Cash | 9.50M |
| Net Cash Per Share | $2.98 |
| Equity (Book Value) | 10.40M |
| Book Value Per Share | 3.28 |
| Working Capital | 7.02M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.37M |
| Capital Expenditures | -160,000 |
| Depreciation & Amortization | 1.02M |
| Net Borrowing | n/a |
| Free Cash Flow | -20.53M |
| FCF Per Share | -$6.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | 69.76% |
| Operating Margin | -1,975.99% |
| Pretax Margin | -1,977.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -64.79% |
| Shareholder Yield | -64.79% |
| Earnings Yield | -582.39% |
| FCF Yield | -385.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $61.25 |
| Price Target Difference | 3,567.67% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 224.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -15.13 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |